Filtered By:
Nutrition: Omega 3
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 227 results found since Jan 2013.
Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)
CONCLUSIONS: Among patients receiving statins, cardiovascular event incidence did not differ significantly between O3AEE-treated patients and non-O3AEE-treated patients. Further studies are required before definitive conclusions can be drawn on the effect of O3AEE on cardiovascular event incidence in high-risk patients with hypertriglyceridemia.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02285166.PMID:35772177 | DOI:10.1080/14740338.2022.2094914
Source: Expert Opinion on Drug Safety - June 30, 2022 Category: Drugs & Pharmacology Authors: Tamio Teramoto Hisao Ogawa Hirotsugu Ueshima Yasushi Okada Kazuo Haze Shigeyuki Matsui Keita Fujikawa Takamasa Hashimoto Sho Sakui Kunihiko Nishimura Mika Kajita Atsushi Horimoto Jovelle Fernandez Source Type: research
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
ConclusionsIcosapent ethyl is cost effective for primary and secondary cardiovascular prevention at an annual price of £2064 in the UK. For PCSK9 inhibitors, price discounts or prescription restrictions are necessary to achieve cost effectiveness.Graphical abstract
Source: Clinical Drug Investigation - July 11, 2022 Category: Drugs & Pharmacology Source Type: research
Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)
CONCLUSIONS: Among patients receiving statins, cardiovascular event incidence did not differ significantly between O3AEE-treated patients and non-O3AEE-treated patients. Further studies are required before definitive conclusions can be drawn on the effect of O3AEE on cardiovascular event incidence in high-risk patients with hypertriglyceridemia.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02285166.PMID:35772177 | DOI:10.1080/14740338.2022.2094914
Source: Expert Opinion on Drug Safety - June 30, 2022 Category: Drugs & Pharmacology Authors: Tamio Teramoto Hisao Ogawa Hirotsugu Ueshima Yasushi Okada Kazuo Haze Shigeyuki Matsui Keita Fujikawa Takamasa Hashimoto Sho Sakui Kunihiko Nishimura Mika Kajita Atsushi Horimoto Jovelle Fernandez Source Type: research
Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality
CONCLUSIONS: Higher concentrations of marine-derived omega-3 PUFA biomarkers were associated with a significantly reduced risk of total CVD, CHD, and total mortality. Levels of ALA were inversely associated with a lower risk of T2D but not CVD-related outcomes. These data support the dietary recommendations advocating the role of omega-3 PUFAs in maintaining an overall lower risk of developing cardiovascular disease and premature deaths.PMID:35830775 | DOI:10.1016/j.clnu.2022.06.034
Source: Clinical Colorectal Cancer - July 13, 2022 Category: Cancer & Oncology Authors: Hong Jiang Lina Wang Duolao Wang Ni Yan Chao Li Min Wu Fan Wang Baibing Mi Fangyao Chen Wanru Jia Xi Liu Jiaxin Lv Yan Liu Jing Lin Le Ma Source Type: research
Eicosapentaenoic Acid for Cardiovascular Events Reduction- Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
CONCLUSIONS: Our analyses demonstrate that although EPA supplementation lowers risk of coronary revascularization more than other oils, there may not be a benefit relative to standard of care. Further, EPA reduces the risk of cardiovascular events only in comparison to mineral oil and not when compared with other placebo oils or controls. In contrast, combined EPA+DHA was associated with reduced risk of cardiovascular death compared to controls.PMID:35914996 | DOI:10.1016/j.jjcc.2022.07.008
Source: Journal of Cardiology - August 1, 2022 Category: Cardiology Authors: Yujiro Yokoyama Toshiki Kuno Sae X Morita Leandro Slipczuk Hisato Takagi Alexandros Briasoulis Azeem Latib Sripal Bangalore Sean P Heffron Source Type: research
Study Protocol and Baseline Characteristics of Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, The Combination of a Randomized Control Trial and an Observational Biomarker Study
CONCLUSIONS: After this study is completed, we will have further evidence on whether a highly purified EPA is effective in reducing cardiovascular events for secondary prevention or not, as well as whether if EPA/AA ratio is a predictor for future cardiovascular events.PMID:36372250 | DOI:10.1016/j.ahj.2022.11.008
Source: Cancer Control - November 13, 2022 Category: Cancer & Oncology Authors: Yuji Nishizaki Katsumi Miyauchi Hiroshi Iwata Teruo Inoue Atsushi Hirayama Kazuo Kimura Yukio Ozaki Toyoaki Murohara Kenji Ueshima Yoshihiro Kuwabara Sachiko Tanaka-Mizuno Naotake Yanagisawa Tosiya Sato Hiroyuki Daida Source Type: research
The 5 Best Ways to Control High Cholesterol, According to People With the Condition
There are a variety of factors that influence cardiovascular risk—but cholesterol is one of the first things that doctors pay attention to.
Having high levels of low-density lipoprotein (LDL) cholesterol is “definitely a variable we try to manage, because it’s been shown to be problematic for heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health.
Though it’s often called the “bad” kind of cholesterol, LDL cholesterol makes up most of your body’s cholesterol stores. That means it’s not a villain on its own, but when levels start creeping ...
Source: TIME: Health - January 18, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news
The Potential Cardiometabolic Effects of Long-Chain Omega-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies
Adv Nutr. 2023 Apr 7:S2161-8313(23)00283-1. doi: 10.1016/j.advnut.2023.03.014. Online ahead of print.ABSTRACTVarious health-related effects of long-chain (LC) omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been suggested. LC omega-3 PUFAs reduce triglyceride levels and have anti-inflammatory, immunomodulatory, antiplatelet, and vascular protective effects. Controversially, they might help in restoring glucose homeostasis via the gut microbiota. However, previous studies have not shown the clear benefits of LC omega-3 PUFAs for cardiovascular diseases. REDUCE-IT...
Source: Atherosclerosis - April 9, 2023 Category: Cardiology Authors: Jae Hyun Bae Hyunjung Lim Soo Lim Source Type: research
